Senti Biosciences Holdings, Inc.
Senti Biosciences is a clinical-stage biotechnology company developing cell and gene therapies for patients with incurable diseases. Its synthetic biology platform uses gene circuits designed to program cells to sense biological signals, make decisions and respond to their environment. The company’s lead candidate, SENTI-202, is an off-the-shelf CAR-NK cell therapy being studied in a Phase 1 trial in the United States and Australia for relapsed or refractory blood cancers, including acute myeloid leukemia. Its pipeline also includes a preclinical solid tumor cell therapy program and a regenerative medicine collaboration with BlueRock Therapeutics. Senti develops therapies primarily for cancer and plans to commercialize them if approved. It also pursues partnerships for programs beyond oncology. GeneFab conducts clinical manufacturing of its CAR-NK pipeline under a service contract. Senti Biosciences is headquartered in South San Francisco, California.
No SEC Form 4 filings for $SNTI in the last 30 days.
See all $SNTI insider activity →Senti Biosciences Holdings, Inc. (SNTI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry Into a Material Definitive Agreement. On November 9, 2026, Senti Biosciences Holdings, Inc., a Delaware corporation (the “Company”), entered into a new equity commitment letter (the “Equity Commitment Letter”), with CPIF II-9 Limited, an entity affiliated with Cel
SNTI (Senti Biosciences) will report Q3'26 earnings on November 12. Analysts expect 0 USD revenue and a loss of 0.21 USD per share. Details are available on the company's financials page.
Edward Mathers resigned from the Board and all committees of Senti Biosciences, effective immediately. The company did not disclose reasons or replacements. This change was reported in an SEC filing.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning SNTI (Senti Biosciences Holdings, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent SNTI coverage spans corporate actions, mergers & acquisitions and earnings.
The financing provides needed capital but introduces dilution risk.
Zero revenue guidance suggests severe operational issues, likely triggering sell pressure.
The sudden board resignation may create short‑term uncertainty for investors.
Resignation may raise governance concerns; CVR distribution could dilute existing shareholders.
The merger and milestone payments could boost future cash flow, but immediate impact may be limited.
AlphAI scores every news story that mentions SNTI with an AI model for sentiment and relevance, and aggregates insider trades from Senti Biosciences Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Senti Biosciences Holdings, Inc. (SNTI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry Into a Material Definitive Agreement. On November 9, 2026, Senti Biosciences Holdings, Inc., a Delaware corporation (the “Company”), entered into a new equity commitment letter (the “Equity Commitment Letter”), with CPIF II-9 Limited, an entity affiliated with Cel
SNTI (Senti Biosciences) will report Q3'26 earnings on November 12. Analysts expect 0 USD revenue and a loss of 0.21 USD per share. Details are available on the company's financials page.
Edward Mathers resigned from the Board and all committees of Senti Biosciences, effective immediately. The company did not disclose reasons or replacements. This change was reported in an SEC filing.
Senti Biosciences Holdings, Inc. (SNTI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 27, 2026, Edward Mathers notified the Board of Directors (the "Board") of Senti Biosciences Holdings, Inc. (the
Senti Biosciences completed a merger, securing up to $60M in milestone payments for SENTI-202. It acquired Rett Syndrome and TIL program assets, raised $2.5M via share issuance, and will exchange $16M in convertible notes for stock by Oct 28.
Senti Biosciences Holdings, Inc. (SNTI) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 SENTI BIOSCIENCES HOLDINGS, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION The following unaudited pro forma condensed consolidated financial information presents the historical financial information of Senti Biosciences Holdings, Inc. (the “Co
Senti Biosciences Holdings, Inc. (SNTI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. (a)(b) On October 15, 2026, Senti Biosciences Holdings, Inc. (the “Company”) reconvened its virtual 2026 Annual Meeting of Stockholders (the “Annual Meeting”), which had been adjourned from October 8, 2026. The propos
Senti Biosciences Holdings, Inc. (SNTI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 23, 2026, Brenda Cooperstone, Ph.D., notified the Board of Directors (the "Board") of Senti Biosciences Holdi
Senti Biosciences Holdings, Inc. (SNTI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry Into a Material Definitive Agreement. Additional Notes On September 3, 2026, Senti Holdings, Inc. (“Senti Holdings”), a wholly owned subsidiary of Senti Biosciences Holdings, Inc. (the “Company”), completed the previously announce issuance and sale to NSG BioInnov
Senti Biosciences Holdings, Inc. (SNTI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry Into a Material Definitive Agreement. On September 1, 2026, the Securities Purchase Agreement, dated April 27, 2026 (the “Purchase Agreement”), by and among the Senti Biosciences Holdings, Inc. (the “Company”), Senti Holdings, Inc (“Senti Holdings” or “Midco”), Se
